Get started
Author

Rina Sor

Observed name: Sor, Rina
ORCID: 0000-0003-2042-5746
Observed ORCID: 0000-0003-2042-5746
OpenAlex ID: A5080637780
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2022 · Samantha B. Kemp, Noah Cheng, et al. · Cancer Discovery · 366
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
2024 · Urszula N. Wasko, Jingjing Jiang, et al. · Nature · 205
T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma
2025 · Margo Orlen, William P. Vostrejs, et al. · Cancer Discovery · 53
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
2019 · Ceire A. Hay, Rina Sor, et al. · Journal of Visualized Experiments · 10
PDF
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma
2023 · Urszula N. Wasko, Jingjing Jiang, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 9
PDF
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
2026 · Minh T. Than, Lucie Dequiedt, et al. · Science · 7
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
2024 · Urszula N. Wasko, Jingjing Jiang, et al. · Nature · 5
PDF
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
2019 · Ceire A. Hay, Rina Sor, et al. · Journal of Visualized Experiments · 5
Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environment
2022 · Vivien Maltez, Charu Arora, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
PDF
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment
2026 · Vivien I. Maltez, Charu Arora, et al. · Immunity · 2
Abstract A014: Inhibition of KrasG12D with a novel small molecule inhibitor alters the pancreatic cancer microenvironment
2023 · Samantha B. Kemp, Noah Cheng, et al. · Molecular Cancer Research · 1
Abstract NG04: Agonistic anti-CD40 converts regulatory T cells in to Type 1 effector cells within the tumor microenvironment
2023 · Vivien Maltez, Charu Arora, et al. · Cancer Research · 1
Abstract LB406: Active RAS inhibition intercepts pancreas cancer in mice
2026 · Minh T. Than, Lucie Dequiedt, et al. · Cancer Research
Supplementary Materials from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2025 · Samantha B. Kemp, Noah Cheng, et al.
PDF
Supplementary Table from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2025 · Samantha B. Kemp, Noah Cheng, et al.
Supplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2025 · Samantha B. Kemp, Noah Cheng, et al.
PDF
Supplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2025 · Samantha B. Kemp, Noah Cheng, et al.
PDF
Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2025 · Samantha B. Kemp, Noah Cheng, et al.
PDF
Supplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2025 · Samantha B. Kemp, Noah Cheng, et al.
PDF
Supplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2025 · Samantha B. Kemp, Noah Cheng, et al.
PDF
Supplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
2025 · Samantha B. Kemp, Noah Cheng, et al.
PDF
Data from T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma
2025 · Margo Orlen, William P. Vostrejs, et al.
Supplementary Table S1 from T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma
2025 · Margo Orlen, William P. Vostrejs, et al.
Supplementary Figure S12 from T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma
2025 · Margo Orlen, William P. Vostrejs, et al.
PDF
Supplementary Figure S2 from T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma
2025 · Margo Orlen, William P. Vostrejs, et al.
PDF
Works count: 62
Citation count: 669
H-index: 6
I10-index: 4
Year
Topic
Type